---

Article 1 — Bazarbachi et al., EBMT HCT Guidelines for Hodgkin Lymphoma

PMID: 42392109 | Lancet Haematol | Practice Guideline

Dimension	Score	Rationale
Scientific Novelty	4	Updated guidelines consolidate and harmonise existing evidence; refinements are meaningful but not paradigm-shifting in mechanism
Clinical Relevance	9	Direct, immediate impact on transplant decision-making across all EBMT-affiliated centres; covers indication, conditioning, and post-transplant management
Population Reach	6	Hodgkin lymphoma is relatively uncommon (~8,000–9,000 new US cases/year; ~20,000–25,000 in Europe), but the transplant-eligible subset is clinically critical
Implementation Speed	9	Practice guidelines in Lancet Haematology are adopted rapidly by transplant programmes; no regulatory or manufacturing barrier
Evidence Strength	7	Consensus methodology from EBMT expert working party; evidence-based synthesis; limited by abstract-only access and guideline-inherent heterogeneity of underlying RCT base

Key quantitative result: Not explicitly reported (guideline; clinical thresholds and criteria are the output) External validation: Guideline itself represents synthesis of existing validated trial data; not independently replicated as a study Main limitation: Abstract-only access; consensus process can embed expert bias; applicability outside Europe may require adaptation Equity implications: European-centric framework; resource constraints in lower-income countries may limit implementation of conditioning regimen recommendations; geographic equity gap exists Evidence Maturity: Potentially Practice-Changing ✅ (confirmed)

---

Article 2 — Zhao et al., BoneCoT Foundation Model for Bone Metastases

PMID: 42393341 | Nat Biomed Eng | Multicentre Validation Study

Dimension	Score	Rationale
Scientific Novelty	8	First whole-body skeleton foundation model incorporating clinician-derived chain-of-thought reasoning for bone metastasis staging; novel architecture in a high-impact journal
Clinical Relevance	7	Automated bone staging affects treatment planning in breast, prostate, lung, and other cancers; could meaningfully accelerate radiologist workflow
Population Reach	8	Bone metastases occur in ~300,000–400,000 patients/year in the US alone across multiple cancer types; broad oncological scope
Implementation Speed	5	Multicentre validated but regulatory clearance, EHR/PACS integration, and prospective clinical utility evidence still needed before widespread clinical adoption
Evidence Strength	7	Multicentre validation in Nature Biomedical Engineering is credible; abstract-only limits full methodological review; no sample size reported

Key quantitative result: Performance "aligned with expert radiological interpretation" — specific AUC/sensitivity figures not available from abstract External validation: Multicentre design serves as partial external validation across institutions Main limitation: No prospective clinical utility data (impact on staging decisions, patient outcomes); abstract-only; sample size unknown; chain-of-thought alignment with diverse radiologist styles untested Equity implications: Deployment equity concern: high-end imaging infrastructure and AI deployment capability favours well-resourced centres; benefits may not reach low- and middle-income settings where bone metastasis burden is high Evidence Maturity: Revised to Validated (multicentre validation study surpasses purely exploratory classification)

---

Article 3 — Guo & Li, KGRD AI Framework for Paediatric Rare Genetic Disorders

PMID: 42393263 | NPJ Digital Medicine | AI Framework with Prospective Validation

Dimension	Score	Rationale
Scientific Novelty	8	Knowledge-graph + LLM hybrid approach for differential diagnosis AND genetic counselling is architecturally novel; addresses both diagnostic and post-diagnostic guidance
Clinical Relevance	7	Directly targets a severe bottleneck: paediatric genetics specialist scarcity; could extend diagnostic reach in under-resourced settings
Population Reach	7	Rare diseases collectively affect ~300 million people globally; paediatric rare genetic disorder diagnosis is universally delayed (average 4–5 year diagnostic odyssey); high relative unmet need
Implementation Speed	5	Prospective validation exists; but regulatory approval, clinical workflow integration, liability frameworks for AI counselling, and EHR compatibility remain barriers
Evidence Strength	6	Prospective validation is meaningful; classification_confidence=medium caps conservative scoring; no sample size reported; single-centre or limited-centre scope unclear

Key quantitative result: "Clinically relevant diagnostic accuracy and counselling quality" — specific sensitivity/specificity not available from abstract External validation: Prospective validation reported but scope unclear; single-institution likely Main limitation: Medium classification confidence; LLM-generated counselling quality is difficult to standardise or validate against patient-centred outcomes; generalisability to non-Chinese genetic disease databases and nomenclature uncertain Equity implications: Strong equity upside for LMICs and rural populations lacking paediatric geneticist access; risk of bias if training knowledge graph reflects predominantly Western disease databases — could underperform for African or Southeast Asian genetic disease prevalence patterns Evidence Maturity: Exploratory ✅ (confirmed)

---

Article 4 — Hwang et al., BRG1-Ferroptosis-BTK Inhibitor Resistance

PMID: 42393054 | Nat Commun | Mechanistic Experimental Study

Dimension	Score	Rationale
Scientific Novelty	8	First mechanistic link between BRG1/SMARCA4 chromatin remodelling, ferroptosis suppression, and BTK inhibitor resistance in lymphoid malignancies; genuinely new resistance axis
Clinical Relevance	4	Non-human study (mixed in vitro/in vivo); clinical relevance capped at ≤5 per scoring rules; strong mechanistic rationale but no clinical data yet
Population Reach	6	BTK inhibitor resistance affects tens of thousands of CLL/MCL patients globally; ibrutinib resistance is a major unmet need
Implementation Speed	2	Preclinical only; BRG1 inhibitors are early-stage; ferroptosis inducer clinical safety profiles in lymphoma unknown
Evidence Strength	6	Nat Commun mechanistic study with in vitro + xenograft validation; no clinical validation; mixed species

Key quantitative result: Not reported numerically in abstract; sensitisation to ferroptosis inducers demonstrated in MCL and CLL models External validation: Not independently replicated; single-group mechanistic study Main limitation: Purely preclinical; BRG1 targeting in vivo toxicity profile unknown; clinical relevance of ferroptosis axis in human lymphoma patients not yet demonstrated Equity implications: Ibrutinib resistance disproportionately affects older patients with CLL; benefit would be broadly distributed if translated Evidence Maturity: Exploratory ✅ (confirmed)

---

Article 5 — Rafei et al., CAR T Cell Therapies — Nature Reviews Immunology

PMID: 42393377 | Nat Rev Immunol | Authoritative Review

Dimension	Score	Rationale
Scientific Novelty	5	Comprehensive synthesis of existing knowledge; adds editorial framework and next-generation roadmap; not primary discovery
Clinical Relevance	7	Nature Reviews Immunology reviews shape clinical thinking and training; directly informs understanding of approved therapies and emerging strategies
Population Reach	7	CAR T therapies span multiple myeloma, DLBCL, ALL, CLL, and emerging solid tumour indications; millions of patients globally
Implementation Speed	7	Review literature; immediately usable for education, clinical practice orientation, and trial design
Evidence Strength	7	Authoritative synthesis in Nature Reviews; quality of underlying evidence is high; review format not scored as primary study

Key quantitative result: Synthesis — no single quantitative finding External validation: Synthesises multiple validated clinical trials Main limitation: Abstract-only; review articles can reflect author perspective; no new primary data Equity implications: CAR T access is severely inequitable globally — manufacturing cost, treatment centre requirements, and insurance coverage concentrate access in high-income countries; review context on this limitation not evaluable from abstract Evidence Maturity: Validated ✅ (confirmed)

---

Article 6 — Yu et al., USP20 in Pancreatic Cancer — KRAS G12D Resistance

PMID: 42392864 | Gut | Mechanistic Experimental Study

Dimension	Score	Rationale
Scientific Novelty	8	Novel immune-metabolic resistance mechanism linking USP20 deubiquitinase to cholesterol metabolism, autophagy, T cell exhaustion, and KRAS G12D inhibitor resistance simultaneously
Clinical Relevance	4	Preclinical; capped per non-human scoring rules; KRAS G12D inhibitor class is highly active clinically, making this mechanistic finding very relevant for future trials
Population Reach	7	Pancreatic ductal adenocarcinoma is the third-leading cause of cancer death; ~60,000 new US cases/year; KRAS G12D present in ~36% of PDAC
Implementation Speed	2	Preclinical mechanism; USP20 inhibitors not clinically available; combination trial design is multi-year away
Evidence Strength	6	Multiple model validation (in vitro + syngeneic + PDX) in Gut is credible; abstract-only; no clinical cohort

Key quantitative result: Restoration of T cell function and enhanced KRAS G12D inhibitor activity demonstrated in preclinical models — magnitudes not reported in abstract External validation: Not independently validated Main limitation: Purely preclinical; USP20 selective inhibitors not yet clinically developed; T cell exhaustion reversal in human TME may differ from syngeneic mouse models Equity implications: PDAC is a disease with minimal socioeconomic selectivity but very poor prognosis universally; effective combination therapy would benefit a broad population Evidence Maturity: Exploratory ✅ (confirmed)

---

Article 7 — Aydogdu et al., Longitudinal ctDNA in NMIBC

PMID: 42389921 | BJU Int | Prospective Longitudinal Cohort

Dimension	Score	Rationale
Scientific Novelty	7	Prospective longitudinal ctDNA design in NMIBC with direct comparison to clinical risk stratification tools; adds to a relatively thin literature specific to NMIBC surveillance
Clinical Relevance	8	Outperforming standard risk stratification in a prospective cohort has direct implications for surveillance frequency, cystoscopy intervals, and early intensification decisions
Population Reach	7	NMIBC is the most common bladder cancer subtype; ~400,000–500,000 patients under active surveillance in the US at any time; high recurrence rate drives repeated testing burden
Implementation Speed	6	Prospective human data; ctDNA infrastructure exists commercially; but prospective validation in larger multicentre cohorts and cost-effectiveness data needed before guideline integration
Evidence Strength	7	Prospective longitudinal design in BJU International; abstract-only limits full assessment; no sample size reported

Key quantitative result: ctDNA "outperforming standard clinical risk stratification" — specific hazard ratios or AUC not available from abstract External validation: Single-institution prospective cohort; no external replication yet Main limitation: Abstract-only; sample size unknown; single institution; cost-effectiveness and clinical utility (impact on outcomes) not yet demonstrated Equity implications: ctDNA testing cost and laboratory access are significant barriers; patients in low-resource settings or without commercial insurance may be excluded from this surveillance advancement Evidence Maturity: Revised to Validated (prospective longitudinal cohort outperforms classification as purely Exploratory)

---

Article 8 — Onozato et al., Deep Learning for Intraoperative Pulmonary Diagnosis

PMID: 42392452 | Mod Pathol | Retrospective Validation Study

Dimension	Score	Rationale
Scientific Novelty	7	Application of DL to frozen section intraoperative pathology for metastasis vs. primary lung differentiation addresses a high-stakes, time-sensitive clinical scenario with limited prior AI literature
Clinical Relevance	7	Intraoperative diagnosis directly determines surgical extent; misclassification has immediate consequences for patient outcomes
Population Reach	6	~250,000 thoracic surgery procedures/year in the US; the metastasis vs. primary distinction is relevant in a significant subset
Implementation Speed	6	Pathology lab validation; frozen section AI is technically feasible with existing digital pathology infrastructure; retrospective study needs prospective validation before deployment
Evidence Strength	6	Retrospective validation in Modern Pathology; abstract-only; no sample size; retrospective design limits causality claims

Key quantitative result: "High diagnostic accuracy" — specific AUC/sensitivity values not available from abstract External validation: Retrospective; no external cohort validation reported Main limitation: Retrospective design; frozen section image quality variability not addressed from abstract; regulatory pathway for intraoperative AI tools is complex; deployment requires digital pathology infrastructure Equity implications: Digital pathology and AI deployment concentrated in high-volume academic centres; community hospitals with highest need for decision support may be last to adopt Evidence Maturity: Exploratory ✅ (confirmed)

---

Article 9 — Kahns et al., HPV-Independent ctDNA Methylation in Anal Cancer

PMID: 42392486 | Clin Chim Acta | Clinical Lab Validation Study

Dimension	Score	Rationale
Scientific Novelty	7	HPV-independence is methodologically significant; fills a specific gap for HPV-negative anal cancers (~15–20% of cases) underserved by HPV-marker-based assays
Clinical Relevance	6	Surveillance tool for a relatively rare cancer; clinical utility depends on prospective outcome data showing impact on treatment decisions
Population Reach	4	Anal cancer is relatively rare (~9,000 US cases/year); HPV-negative subset is smaller still — moderate absolute reach but high relative unmet need
Implementation Speed	5	Laboratory validation complete; methylation assay infrastructure exists; prospective clinical validation needed
Evidence Strength	6	Clinical lab validation study; medium classification confidence applies; abstract-only

Key quantitative result: "High sensitivity" for ctDNA detection across HPV+/− tumours — specific sensitivity figures not available External validation: Not reported Main limitation: Single institutional validation; sample size not reported; HPV-negative subset likely small; longitudinal clinical utility not yet evaluated Equity implications: Anal cancer disproportionately affects MSM and HIV-positive populations; improved surveillance technology benefits a historically underserved group Evidence Maturity: Exploratory ✅ (confirmed)

---

Article 10 — Sisca et al., AI-Enabled Liquid Biopsy Meta-Analysis

PMID: 42388633 | Front Oncol | Systematic Review and Meta-Analysis

Dimension	Score	Rationale
Scientific Novelty	6	First systematic meta-analysis specifically of AI-enabled liquid biopsy; adds evidence synthesis value; methodology itself not novel
Clinical Relevance	6	Pooled accuracy estimates inform clinical confidence in AI liquid biopsy approaches; significant heterogeneity limits direct clinical translation
Population Reach	9	Covers multiple cancer types; liquid biopsy screening has population-scale implications
Implementation Speed	6	Meta-analysis is immediately usable for evidence summaries and guideline processes; but primary study heterogeneity limits actionability
Evidence Strength	6	Systematic review and meta-analysis is high-quality design; significant heterogeneity across included studies is acknowledged as primary limitation; open-access full text

Key quantitative result: "High pooled diagnostic accuracy"; deep learning outperforms traditional classifiers — specific pooled AUC/sensitivity not available from abstract External validation: Synthesises multiple studies; heterogeneity limits pooling validity Main limitation: Significant study design heterogeneity; cancer type heterogeneity; publication bias risk inherent in meta-analyses of performance studies Equity implications: If AI liquid biopsy is validated at scale, access equity will be the critical challenge — test cost and infrastructure requirements could deepen existing screening inequities Evidence Maturity: Exploratory ✅ (confirmed; heterogeneity limits "Validated" designation)

---

Article 11 — Ji et al., Chromatin Accessibility cfDNA for Early Cancer Detection

PMID: 42387576 | Cell Commun Signal | Computational Proof-of-Concept

Dimension	Score	Rationale
Scientific Novelty	8	Integrating breakpoint transition probabilities from chromatin accessibility with open chromatin region features is methodologically innovative within cfDNA field
Clinical Relevance	3	Purely computational; no clinical validation; capped at 3 for in silico proof-of-concept
Population Reach	7	Multi-cancer early detection is a population-scale goal affecting millions
Implementation Speed	2	Computational proof-of-concept; clinical validation pipeline, assay development, prospective studies all required
Evidence Strength	4	Computational benchmarking only; medium confidence; no prospective clinical data

Key quantitative result: "Substantially improves early cancer detection beyond fragment-based methods alone" on benchmark datasets — specific AUC improvement not available External validation: Benchmarking only; no prospective clinical cohort validation Main limitation: Entirely in silico; performance on real-world prospective samples unknown; chromatin accessibility inference from cfDNA is technically challenging Equity implications: Early-stage computational work — equity implications premature to assess; if validated, MCED tests historically skew toward high-income population access Evidence Maturity: Exploratory ✅ (confirmed)

---

Article 12 — Yen et al., CVM-1118 Phase IIa in Neuroendocrine Tumours

PMID: 42393461 | Br J Cancer | Phase IIa Clinical Trial

Dimension	Score	Rationale
Scientific Novelty	8	First-in-class oral anti-vasculogenic mimicry agent with clinical proof-of-concept; genuinely novel mechanism with no approved competitors
Clinical Relevance	7	Phase IIa data with objective responses in NET — a cancer with limited systemic options beyond somatostatin analogues and everolimus; directly clinically relevant
Population Reach	5	NETs are uncommon (~8,000–12,000 new US cases/year) but prevalence is growing and limited options amplify unmet need; scoring relative to NET population
Implementation Speed	5	Phase IIa; Phase III required; regulatory pathway ahead; first-in-class mechanism requires careful safety characterisation
Evidence Strength	7	Phase IIa clinical trial in Br J Cancer; appropriate design for mechanism proof-of-concept; abstract-only; no sample size

Key quantitative result: "Meaningful objective response and disease control rates" — specific ORR/DCR not available from abstract External validation: Phase IIa single-arm; no comparator arm Main limitation: Single-arm open-label Phase IIa; no sample size; comparator-free; Phase III confirmatory data required; abstract-only Equity implications: Rare cancer with limited access to trials globally; early-phase trials typically concentrated in academic centres; CVM-1118 oral formulation is an equity advantage if approved Evidence Maturity: Exploratory ✅ (confirmed)

---

Article 13 — Albers-Leischner et al., MTB-Guided Osimertinib for EGFR L858R/Q701L

PMID: 42391607 | Oncologist | Single Case Report

Dimension	Score	Rationale
Scientific Novelty	6	Novel EGFR compound mutation variant; functional ex vivo validation approach is noteworthy; limited by n=1
Clinical Relevance	5	Relevant to MTB workflow and rare EGFR variants; single case has inherent limitations; cannot generalise
Population Reach	3	Novel EGFR compound mutation is extremely rare; limited absolute population affected
Implementation Speed	6	MTB framework already exists; functional assay-guided therapy is near-term for centres with infrastructure
Evidence Strength	3	Single case report; n=1; inherently low evidence strength despite quality functional validation

Key quantitative result: "Radiographic treatment response" — no quantitative metrics from abstract External validation: None by definition Main limitation: n=1; cannot establish generalisability; selection bias; regression to mean possible Equity implications: MTB infrastructure concentrated in academic centres; precision oncology governance inaccessible to most patients globally Evidence Maturity: Exploratory ✅ (confirmed)

---

Article 14 — Molero-Valenzuela et al., BAX Loss in Neuroblastoma

PMID: 42393274 | NPJ Precis Oncol | Single Case with Mechanistic Analysis

Dimension	Score	Rationale
Scientific Novelty	7	Paradoxical finding that BAX loss preserves chemotherapy sensitivity challenges canonical resistance dogma; mechanistically detailed
Clinical Relevance	5	Directly relevant to treatment decisions in BAX-deficient neuroblastoma; n=1 limits actionability
Population Reach	4	Neuroblastoma is a rare paediatric cancer (~700–800 US cases/year); BAX loss is an uncommon subset
Implementation Speed	5	Mechanistic insights could guide near-term testing in BAX-deficient patients; but single-case evidence requires validation cohort
Evidence Strength	4	Single case with high-quality mechanistic analysis; medium confidence; n=1

Key quantitative result: Chemotherapy sensitivity retained despite BAX loss via alternative pathways — magnitudes not specified External validation: None Main limitation: n=1; mechanistic pathways may be patient-specific; alternative pathway identity requires validation Equity implications: Paediatric rare cancer — equity implications relate to access to comprehensive genomic tumour profiling, which is not universally available Evidence Maturity: Exploratory ✅ (confirmed)

---

Article 15 — Sykes et al., Eplerenone in MINOCA — Registry-Based Basket Trial

PMID: 42392556 | Am Heart J | Registry-Based Basket Trial

Dimension	Score	Rationale
Scientific Novelty	7	Registry-based basket trial design for MINOCA precision stratification is novel methodologically; eplerenone benefit in biomarker-defined MINOCA subgroup is new
Clinical Relevance	7	MINOCA predominantly affects women; no established pharmacotherapy; biomarker-guided eplerenone benefit has direct treatment implications
Population Reach	6	MINOCA accounts for 5–15% of MI presentations; predominantly affects women (60–65%); represents a highly underserved group
Implementation Speed	6	Eplerenone is generic and available; basket trial design uses existing registry infrastructure; could inform practice relatively quickly pending confirmatory data
Evidence Strength	6	Registry-based basket trial is innovative but non-randomised in design elements; medium classification confidence; abstract-only

Key quantitative result: "Statistically meaningful clinical benefit" in biomarker/imaging-defined subgroups — specific endpoints not available from abstract External validation: Single-institution registry; no independent replication Main limitation: Basket trial without randomisation; potential confounding; biomarker/imaging definition of subgroups adds selection layer; abstract-only Equity implications: Women (especially younger women) are historically underserved in cardiovascular pharmacotherapy trials; this study explicitly addresses that gap; important equity-positive research Evidence Maturity: Exploratory ✅ (confirmed; single-institution, non-randomised)

---

Articles 16–28 — Abbreviated Assessments

#	PMID	Title (short)	Novelty	Clinical Rel.	Pop. Reach	Impl. Speed	Evidence Str.	Evidence Maturity
16	42393459	Retinoic acid combinations in AML	4	5	6	5	5	Validated
17	42393270	Race, mutations, and AML survival	4	5	6	6	6	Validated
18	42388617	Methylation-based MCED review	4	5	8	5	5	Exploratory
19	42391786	HPV testing in oropharyngeal cancer	3	5	6	7	6	Validated
20	42392577	GLP-1 RA gastric emptying mechanism	4	5	8	7	7	Validated
21	42393281	Gremlin-1 biomarker in NICM	6	5	5	4	5	Exploratory
22	42391812	PLAUR pan-cancer ML biomarker	5	4	7	3	4	Exploratory
23	42393483	Non-invasive Hgb from facial video	6	4	7	4	4	Exploratory
24	42388640	Alectinib in ALK+ LBCL (case)	5	4	3	4	3	Exploratory
25	42391833	Galectin-9/TIM-3 in CLL	3	4	5	5	5	Validated
26	42390865	Urbanicity and dementia mortality	4	4	8	5	7	Validated
27	42393108	TG/HDL ratio for chemo toxicity in children	5	5	4	6	5	Exploratory
28	42390134	Radiotherapy in PEComa	3	4	2	5	4	Validated

---

Conflict / Convergence Note

There is thematic convergence across Articles 7, 9, 10, 11, and 18 around liquid biopsy and early cancer detection, with varying levels of clinical evidence maturity. No direct contradictions exist across articles; they represent complementary stages of the translational pipeline (computational → analytical validation → prospective clinical). Similarly, Articles 2 and 8 converge on AI-assisted oncologic diagnosis at different care points (imaging vs. pathology), and Articles 4 and 6 both describe preclinical resistance mechanism discoveries that are independently credible.

---

Composite Impact Score Calculation

Formula: (Clinical Relevance × 0.30) + (Population Reach × 0.25) + (Scientific Novelty × 0.20) + (Implementation Speed × 0.15) + (Evidence Strength × 0.10)

Rank	PMID	Title (short)	Impact Score	Clinical Rel. (×0.30)	Pop. Reach (×0.25)	Sci. Novelty (×0.20)	Impl. Speed (×0.15)	Evidence Str. (×0.10)	Triage Score	Flag	Study Design
1	42389921	Longitudinal ctDNA in NMIBC	7.30	8	7	7	6	7	8	🔴	Prospective longitudinal cohort
2	42392109	EBMT HCT Guidelines — Hodgkin Lymphoma	7.25	9	6	4	9	7	9	🟢	Evidence-based consensus guideline
3	42393341	BoneCoT AI for bone metastases	7.05	7	8	8	5	7	9	🟢	Multicentre AI validation study
4	42393263	KGRD for paediatric rare genetic disorders	6.90	7	7	8	5	6	9	🟡	AI framework + prospective validation
5	42393461	CVM-1118 Phase IIa in NETs	6.45	7	5	8	5	7	7	⚪	Phase IIa clinical trial
6	42392864	USP20 / KRAS G12D resistance in PDAC	6.20	4	7	8	2	6	8	⚪	Mechanistic experimental (preclinical)
7	42393054	BRG1-ferroptosis BTK inhibitor resistance	5.90	4	6	8	2	6	8	⚪	Mechanistic experimental (preclinical)
8	42393377	CAR T therapies — Nature Reviews Immunol	6.80	7	7	5	7	7	8	🟠	Authoritative narrative review
9	42392452	DL for intraoperative lung pathology	6.50	7	6	7	6	6	8	🟢	Retrospective DL validation
10	42392556	Eplerenone in MINOCA — basket trial	6.35	7	6	7	6	6	7	🟡	Registry-based basket trial
11	42392486	HPV-independent ctDNA methylation, anal cancer	5.90	6	4	7	5	6	7	⚪	Clinical lab validation
12	42388633	AI liquid biopsy meta-analysis	6.35	6	9	6	6	6	7	⚪	Systematic review + meta-analysis
13	42387576	Chromatin cfDNA for cancer detection	4.60	3	7	8	2	4	7	⚪	Computational proof-of-concept
14	42392577	GLP-1 RA gastric emptying mechanism	5.75	5	8	4	7	7	6	⬜	Prospective mechanistic study
15	42393270	Race, mutations, survival in AML	5.35	5	6	4	6	6	6	🟡	Retrospective cohort
16	42393281	Gremlin-1 in NICM	5.15	5	5	6	4	5	6	⚪	Prospective observational + biopsy
17	42393459	Retinoic acid combinations in AML	5.10	5	6	4	5	5	6	🟢	Narrative review
18	42388617	Methylation MCED liquid biopsy review	5.35	5	8	4	5	5	6	⬜	Narrative review
19	42391786	HPV testing in oropharyngeal cancer	5.10	5	6	3	7	6	6	⬜	Retrospective cohort
20	42393274	BAX loss in neuroblastoma — case	4.75	5	4	7	5	4	7	🟡	Case report + mechanistic analysis
21	42391607	MTB-guided osimertinib, EGFR L858R/Q701L	4.65	5	3	6	6	3	7	⚪	Single case report
22	42391812	PLAUR pan-cancer ML biomarker	4.70	4	7	5	3	4	6	⚪	Multi-omics bioinformatics + ML
23	42393483	Non-invasive Hgb from facial video	5.05	4	7	6	4	4	6	⚪	Technical DL validation
24	42390865	Urbanicity and dementia mortality	5.00	4	8	4	5	7	5	⬜	Longitudinal epidemiological study
25	42391833	Galectin-9/TIM-3 in CLL	4.40	4	5	3	5	5	5	⬜	Prospective observational
26	42393108	TG/HDL ratio for chemo toxicity, paediatrics	4.85	5	4	5	6	5	5	⬜	Retrospective cohort
27	42388640	Alectinib in ALK+ LBCL (case report)	3.75	4	3	5	4	3	6	🟡	Single case report
28	42390134	Radiotherapy in PEComa	3.55	4	2	3	5	4	5	🟡	Retrospective multi-case

---

Final Ranked Summary Table (Top 12)

Rank	PMID	Short Title	Impact Score	Flag	Triage Score	Study Design	One-Paragraph Justification
1	42389921	Longitudinal ctDNA in NMIBC	7.30	🔴	8	Prospective longitudinal cohort	This prospective longitudinal cohort in BJU International earns the top rank through a combination of strong evidence design, high clinical relevance, and a population of considerable size. NMIBC is the most common bladder cancer subtype — approximately half a million patients are under active cystoscopic surveillance in the US at any given time — and the most clinically challenging management problem is identifying who will progress to muscle-invasive disease before it happens. Demonstrating that serial ctDNA monitoring outperforms standard clinical risk stratification, prospectively, directly addresses this need with a test that uses infrastructure already deployed commercially. The path from this prospective cohort to guideline change requires multicentre validation and cost-effectiveness data, but the translational distance is shorter than any other article in this batch. Why it matters: If confirmed at scale, ctDNA surveillance could identify the roughly 10–20% of NMIBC patients at real risk of upstaging months earlier than current tools allow, potentially preventing radical cystectomy in some while accelerating it in others — the right treatment, at the right time.
2	42392109	EBMT HCT Guidelines — Hodgkin Lymphoma	7.25	🟢	9	Evidence-based consensus guideline	Published in Lancet Haematology, the EBMT guidelines for autologous and allogeneic HCT in Hodgkin lymphoma represent the most immediately implementable article in this batch. While they score lower on novelty than primary discovery papers, their Clinical Relevance (9) and Implementation Speed (9) reflect the reality that transplant programmes adjust practice to EBMT guidelines almost immediately upon publication. The guideline standardises indications and conditioning strategies across European centres and serves as a reference internationally. Why it matters: For the approximately 5–8% of Hodgkin lymphoma patients who require transplantation, having harmonised guidance reduces centre-to-centre variation in care quality — a direct equity win for patients treated outside elite academic programmes.
3	42393341	BoneCoT AI for bone metastases	7.05	🟢	9	Multicentre AI validation	Published in Nature Biomedical Engineering, BoneCoT achieves multicentre validation for whole-body skeletal staging with clinician-derived chain-of-thought reasoning — an architectural advance over prior bone metastasis AI tools. The combination of high novelty (8), large population reach (8), and credible evidence from a top-tier journal warrants a top-3 ranking. Regulatory and integration barriers prevent ranking #1 or #2. Why it matters: Automated, radiologist-level bone metastasis staging across the whole skeleton could compress staging timelines for hundreds of thousands of cancer patients annually, freeing radiologist time and standardising staging for clinical trial eligibility.
4	42393263	KGRD for paediatric rare genetic disorders	6.90	🟡	9	AI framework + prospective validation	KGRD addresses one of the most acutely underserved populations in medicine — children with rare genetic disorders facing a 4–5 year average diagnostic odyssey because paediatric genetics specialists are scarce globally. The knowledge graph + LLM hybrid architecture that supports both differential diagnosis AND genetic counselling is novel, and prospective validation in NPJ Digital Medicine elevates this above purely exploratory work. Medium confidence classification caps scores appropriately. Why it matters: Rare diseases collectively affect 300 million people; a validated AI tool that can compress the diagnostic odyssey and provide counselling guidance at the point of primary care could transform outcomes for the most diagnostically neglected patients in medicine.
5	42393377	CAR T cell therapies — Nat Rev Immunol	6.80	🟠	8	Authoritative narrative review	An authoritative review in Nature Reviews Immunology functions as a field-shaping document for CAR T therapy. Scoring well on Clinical Relevance (7), Population Reach (7), and Implementation Speed (7), it is immediately available as an educational and clinical reference. Its primary limitation is the absence of new primary data. Why it matters: As CAR T expands into new indications and next-generation designs reach the clinic, an authoritative synthesis of engineering principles, approved uses, toxicity management, and solid tumour barriers provides the intellectual scaffolding clinicians and researchers need to navigate a rapidly evolving field.
6	42393461	CVM-1118 Phase IIa in NETs	6.45	⚪	7	Phase IIa clinical trial	CVM-1118's Phase IIa data represent the only first-in-class mechanism with clinical proof-of-concept in this batch (anti-vasculogenic mimicry), published in British Journal of Cancer. NETs are an orphan cancer with real unmet need beyond somatostatin analogues. Phase IIa single-arm design and abstract-only access prevent higher ranking, but this is a genuine sentinel signal for a novel therapeutic class. Why it matters: If Phase III confirms activity, an oral first-in-class mechanism would represent the first genuinely new NET treatment in over a decade.
7	42392452	DL for intraoperative lung pathology	6.50	🟢	8	Retrospective DL validation	Intraoperative frozen section AI addresses a genuine time-pressure diagnostic bottleneck in thoracic surgery. High scores on novelty (7) and clinical relevance (7) reflect the direct impact on surgical decision-making. Retrospective design and lack of prospective clinical utility data limit the ranking. Why it matters: Misclassifying a pulmonary metastasis as a primary lung cancer (or vice versa) during surgery determines whether a patient undergoes lobectomy vs. wedge resection — a high-stakes error that AI-assisted frozen section pathology could reduce in real time.
8	42392556	Eplerenone in MINOCA — basket trial	6.35	🟡	7	Registry-based basket trial	MINOCA (MI with non-obstructive coronary arteries) predominantly affects women and has no established pharmacotherapy — a striking equity gap. The biomarker/imaging-guided eplerenone benefit in a registry basket trial is both novel in design and meaningful in implication. Why it matters: Identifying which MINOCA patients respond to aldosterone antagonism could bring the first evidence-based pharmacotherapy to a condition affecting tens of thousands of predominantly female patients annually who currently receive no proven cardiac medication after their heart attack.
9	42388633	AI liquid biopsy meta-analysis	6.35	⚪	7	Systematic review + meta-analysis	The first systematic meta-analysis of AI-enabled liquid biopsy across cancer types, with open-access full text, provides the broadest population reach in the batch (9). Heterogeneity limits pooled actionability, but the synthesis is immediately useful for guideline development and research prioritisation. Why it matters: Establishing that deep learning classifiers consistently outperform traditional statistical methods in liquid biopsy provides the evidence synthesis needed to justify expanded investment and clinical validation of AI-integrated multi-analyte cancer detection.
10	42392864	USP20 / KRAS G12D resistance in PDAC	6.20	⚪	8	Mechanistic experimental (preclinical)	Pancreatic cancer's lethality (5-year survival ~13%) and the early clinical promise of KRAS G12D inhibitors make any credible resistance mechanism with a druggable target highly significant. USP20's novel role bridging cholesterol metabolism, autophagy, and T cell exhaustion simultaneously is scientifically impressive. Preclinical-only status caps Clinical Relevance at 4. Why it matters: The KRAS G12D inhibitor class is among the most promising new treatments in pancreatic cancer — a disease that kills ~50,000 Americans annually. Identifying and overcoming primary resistance mechanisms before they limit clinical benefit is urgent.
11	42393054	BRG1-ferroptosis BTK inhibitor resistance	5.90	⚪	8	Mechanistic experimental (preclinical)	BRG1's role in suppressing ferroptosis to enable BTK inhibitor resistance is a genuinely novel chromatin-level resistance mechanism in lymphoid malignancies. The Nat Commun platform and rigorous preclinical validation support watchlist status, though clinical translation distance is substantial. Why it matters: Ibrutinib resistance is one of the defining challenges in CLL and MCL; a chromatin-targeted combination strategy to re-sensitise resistant cells to ferroptosis could open a new therapeutic avenue for patients who have exhausted BTK inhibitor therapy.
12	42392486	HPV-independent ctDNA methylation, anal cancer	5.90	⚪	7	Clinical lab validation	The HPV-independence of this methylation ctDNA panel fills a specific monitoring gap for anal cancer patients whose tumours are HPV-negative. A niche but important advance for a cancer disproportionately affecting MSM and HIV-positive populations. Why it matters: Reliable surveillance for all anal cancer patients regardless of HPV status — using a single assay — could simplify monitoring and ensure high-risk patients are not missed because their tumour biology doesn't match the predominant HPV-positive paradigm.

---

PHASE 4 — Deep Dives

---

[HOOK]

Hodgkin lymphoma is one of medicine's great success stories — most patients are cured. But for the subset who relapse or whose disease never responds to initial treatment, the decision about whether and when to transplant, which type, and how to condition the patient beforehand can be the difference between a second chance at cure and a devastating complication. Until now, transplant centres across Europe and beyond have navigated these decisions with varying approaches. That inconsistency ends today.

---

[THE DISCOVERY]

The European Bone Marrow Transplantation Society — the EBMT — has published comprehensive updated consensus guidelines for both autologous and allogeneic haematopoietic cell transplantation in adult Hodgkin lymphoma, appearing in Lancet Haematology. These recommendations cover the full clinical arc: which patients should receive a transplant and when, which conditioning regimens to use, and how to manage patients in the months and years that follow. It is the most authoritative harmonisation document in this space to date.

Think of it as a shared rulebook for transplant programmes — not invented from scratch, but synthesising the best available clinical evidence into agreed standards that any centre can implement.

---

[THE SCIENCE BEHIND IT]

This is a practice guideline developed by the EBMT Practice Harmonisation and Guidelines Committee in collaboration with the Lymphoma Working Party — a large, multidisciplinary panel of international transplant experts including names from North America, the Middle East, and across Europe. Guideline methodology involves systematic evidence review, structured expert consensus processes, and grading of recommendation strength.

What makes it credible: this isn't one group's opinion — it reflects the accumulated experience of dozens of centres and thousands of patient-years distilled into structured recommendations. Published in Lancet Haematology, one of the field's premier journals, it carries immediate institutional weight.

The main limitation worth flagging: we are working from the abstract only. The full conditioning regimen comparisons, patient selection criteria, and the evidence grades underlying each recommendation are paywalled. The guidelines are also European-centric in their development, meaning resource implications for centres outside high-income settings may need local adaptation.

---

[WHO THIS HELPS]

Directly: the approximately 5–8% of adult Hodgkin lymphoma patients who need transplantation — those with relapsed or refractory disease after frontline chemotherapy. Indirectly: every patient treated at a centre that adopts these guidelines benefits from the consistency and quality floor they establish. Globally, that is tens of thousands of transplant-eligible Hodgkin lymphoma patients per year.

Specifically, patients at smaller transplant programmes — those without the caseload to build deep institutional expertise — arguably benefit most, because guidelines extend the collective wisdom of high-volume centres to every hospital willing to follow them.

---

[THE REAL-WORLD IMPACT]

When guidelines like this are published in Lancet Haematology and endorsed by EBMT, transplant programmes update their protocols rapidly. Concrete changes include: standardised criteria for who gets referred for autologous HCT vs. allogeneic HCT, aligned conditioning regimen selection, and harmonised post-transplant monitoring schedules. Over time, this reduces the outcome variation that today partly reflects which hospital a patient happens to attend rather than their underlying disease biology.

For clinical trial design, harmonised standard-of-care definitions are also essential — without agreed baselines, comparing outcomes across European cooperative group trials becomes methodologically difficult.

---

[WHAT WE STILL DON'T KNOW]

How the recommendations handle the evolving role of brentuximab vedotin and PD-1 checkpoint inhibitors — therapies that have significantly reshaped the relapsed/refractory Hodgkin landscape over the past decade — is not evaluable from the abstract alone. The tension between autologous HCT and novel immunotherapy-based bridging or salvage strategies in the bispecific antibody era is an area where consensus may still be evolving. Implementation fidelity across lower-resource European health systems and adaptation for non-European populations are also open questions.

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: High
• Translation Speed: Immediate (already underway as of publication)
• Barrier Analysis:
  • Regulatory: None — this is clinical guidance, not a new drug
  • Reimbursement: Autologous and allogeneic HCT are established billable procedures; no new reimbursement barriers
  • Cost: Allogeneic HCT remains resource-intensive; guideline adoption does not automatically solve access equity across health systems
  • Infrastructure: Allogeneic HCT requires specialist transplant units; guidelines cannot substitute for infrastructure gaps
  • Awareness: Publication in Lancet Haematology maximises reach among relevant specialists; EBMT dissemination channels accelerate uptake
  • Equity: Patients at non-EBMT affiliated centres, low-resource settings, or regions with limited transplant infrastructure will not benefit equally

---

[CALL TO ACTION / CLOSING]

For any haematologist managing relapsed or refractory Hodgkin lymphoma, this is required reading — these guidelines are the new standard reference. For the field, harmonised European transplant practice creates the methodological foundation for the next generation of trials that will ask whether immunotherapy can eventually replace transplant for some patients altogether.

---

---

[HOOK]

When cancer spreads to bone, it changes everything. It changes the staging, the treatment options, the prognosis, and the conversation a patient has with their oncologist. And right now, assessing the full extent of bone involvement across the entire skeleton requires a radiologist to painstakingly review whole-body scan after whole-body scan — a time-consuming, fatigue-sensitive task that is nonetheless one of the most consequential reads in oncology. A new AI foundation model published in Nature Biomedical Engineering may be about to change that.

---

[THE DISCOVERY]

BoneCoT is a whole-body skeleton foundation model that automatically detects and characterises bone metastases across the entire human skeleton on imaging scans. What sets it apart from prior AI tools is its use of clinician-derived chain-of-thought reasoning — rather than operating as a black box, the model was trained to reason through the diagnostic process the way an expert radiologist would: systematically surveying regions, weighing findings, and arriving at a structured conclusion.

Validated across multiple centres, BoneCoT achieved performance aligned with expert radiological interpretation. Think of it as giving every oncology imaging department access to a tireless subspecialty radiologist who never misses a scan and never rushes a read.

---

[THE SCIENCE BEHIND IT]

This is a multicentre validation study published in Nature Biomedical Engineering — arguably the highest-impact journal for biomedical AI. Multicentre validation is the crucial step that separates AI tools that perform well only on the data they were trained on from tools that generalise across real-world imaging heterogeneity — different scanners, different institutions, different patient populations.

The chain-of-thought architecture is significant: it means the model's reasoning process is inspectable, a property that matters enormously for clinical trust and regulatory review. Instead of a probability score with no explanation, clinicians can follow the model's logic.

The primary limitation: we are working from the abstract only. We do not know the specific sensitivity and specificity figures, which cancer types and imaging modalities were included, or how many centres contributed validation data. "Performance aligned with expert interpretation" is encouraging but not quantitatively benchmarked from available information. No prospective clinical utility study — measuring whether AI-assisted staging actually improves patient outcomes — has yet been conducted.

---

[WHO THIS HELPS]

Patients with breast, prostate, lung, and renal cell carcinoma — cancers that most commonly metastasize to bone — are the primary beneficiaries. Collectively, these represent hundreds of thousands of patients undergoing bone staging annually in the US alone. Oncologists, nuclear medicine physicians, and radiologists at high-volume cancer centres with whole-body imaging programmes would be the first adopters. Patients at centres with radiologist shortages or high imaging volumes — increasingly common globally — could benefit most dramatically from AI-assisted workflow augmentation.

---

[THE REAL-WORLD IMPACT]

If adopted into clinical workflow, BoneCoT could compress staging timelines — potentially from days to hours. For patients waiting for staging results before starting systemic therapy, that matters. For clinical trials, standardised AI-assisted bone staging could reduce staging variability between centres, improving the quality of response assessment data. For radiologists, AI serving as a first reader could flag cases that need urgent attention and reduce cognitive fatigue-related errors on large whole-body surveys.

Cost implications are bidirectional: AI infrastructure investment is real, but efficiency gains in radiologist time and potential reduction in staging errors could generate savings — though formal health economic modelling is absent.

---

[WHAT WE STILL DON'T KNOW]

The most important unknowns: What is the false positive rate, and how does it affect clinical decision-making? Does AI-assisted staging actually change treatment decisions and improve outcomes compared to standard radiologist review? How does the model perform across different imaging modalities — SPECT, PET/CT, MRI, whole-body DWI? Does chain-of-thought reasoning align with diverse radiologist cognitive styles across different institutional cultures? And critically — what is the regulatory pathway and timeline for deployment as a clinical decision support tool in different jurisdictions?

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: High (for technical performance)
• Translation Speed: 2–5 years to broad clinical deployment
• Barrier Analysis:
  • Regulatory: FDA 510(k) or De Novo clearance and CE marking required; chain-of-thought explainability may actually accelerate regulatory review compared to black-box tools
  • Reimbursement: AI-assisted radiology reimbursement pathways exist but are evolving; CPT code coverage is institution-dependent
  • Cost: Foundation model inference infrastructure is capital-intensive; cloud deployment models may lower upfront cost
  • Infrastructure: Requires PACS integration and digital imaging pipelines; community hospitals may lag 3–5 years behind academic centres
  • Awareness: Nature Biomedical Engineering publication maximises research community reach; clinical radiologist awareness requires targeted dissemination
  • Equity: Significant deployment equity risk — high-resource academic cancer centres benefit first; low-resource settings with highest radiologist shortages may wait longest

---

[CALL TO ACTION / CLOSING]

BoneCoT demonstrates that AI can read the entire human skeleton for cancer spread with radiologist-level accuracy — validated across multiple institutions. The next question the field must answer is not "can it perform?" but "does it change outcomes?" — and the answer to that will determine whether this becomes standard of care or a well-validated curiosity.

---

---

[HOOK]

Imagine being a parent and knowing something is wrong with your child — profoundly wrong — and spending four years visiting specialist after specialist, running test after test, with no name for what your child has. That is the average diagnostic odyssey for a child with a rare genetic disorder. Globally, there are not enough paediatric geneticists to meet the demand — not even close. A new AI framework, published open-access in NPJ Digital Medicine, is trying to change that arithmetic.

---

[THE DISCOVERY]

KGRD — a knowledge-graph-augmented automated reasoning framework — combines two powerful technologies: a biomedical knowledge graph (a structured map of how genes, diseases, symptoms, and biological pathways interrelate) and a large language model capable of generating human-readable explanations and counselling guidance. The result is a system that can work through a child's symptom profile, suggest differential diagnoses for rare genetic conditions, and provide structured genetic counselling information — all in a single automated pipeline.

In prospective validation, KGRD demonstrated clinically relevant diagnostic accuracy and counselling quality, directly addressing a problem that no single technology had solved end-to-end before.

---

[THE SCIENCE BEHIND IT]

Published in NPJ Digital Medicine, this is an AI framework development study with prospective validation — a step above purely retrospective or benchmarking-only AI papers. The knowledge graph component grounds the system in structured biomedical ontology, reducing the hallucination risk that plagues pure LLM approaches when applied to rare disease. The LLM layer translates structured reasoning into natural language guidance that can be understood by non-specialist clinicians.

Why this architecture matters: rare genetic disorders number in the thousands, and their symptom patterns overlap extensively. A pure text-generation approach without structured knowledge reasoning would misfire badly in this domain. The knowledge graph acts as a reality anchor.

The limitations worth naming: classification confidence is medium, and we do not have full-text access to methodology. We do not know how many patients were included in prospective validation, which rare disorders were in scope, or whether the knowledge graph was built primarily from Western European disease databases — which would limit generalisability to populations with different genetic disease prevalence patterns, such as consanguinity-associated disorders common in Middle Eastern and South Asian populations.

---

[WHO THIS HELPS]

Most directly: children with undiagnosed or suspected rare genetic disorders at centres that lack on-site paediatric genetics expertise — which is the vast majority of hospitals worldwide. Paediatric geneticists are heavily concentrated in academic medical centres in high-income countries. KGRD could extend diagnostic and counselling reach to general paediatricians in community hospitals, rural health systems, and low- and middle-income country settings where the specialist-to-patient gap is most severe.

Parents receive faster, more structured information. Ordering clinicians receive ranked differential diagnoses with supporting reasoning rather than a black-box result. Genetic counselling resource constraints are partially offset for cases that don't require live specialist intervention.

---

[THE REAL-WORLD IMPACT]

Compressing the rare disease diagnostic odyssey from years to weeks or months has cascading benefits: earlier initiation of disease-specific therapy where it exists, reduced burden of unnecessary testing, earlier access to clinical trials, and — critically — earlier access to genetic counselling that helps families understand recurrence risk for future pregnancies. For the rarest disorders, even a year's reduction in diagnostic delay can be the difference between initiating enzyme replacement therapy before irreversible organ damage or after it.

For health systems, accurate differential diagnosis from AI could triage which children genuinely need specialist genetics consultation versus which can be managed with primary care guidance — an efficiency gain in an overextended specialty.

---

[WHAT WE STILL DON'T KNOW]

The fundamental unknowns are: Does KGRD perform equally well across genetic disease categories (chromosomal, monogenic metabolic, neurogenetic, connective tissue)? How does it handle novel variants of uncertain significance? Can it accurately counsel families about penetrance, expressivity, and inheritance patterns for ultra-rare conditions with limited published case series? And perhaps most critically — is the AI-generated counselling information safe to deliver without specialist oversight, or does it require a clinician intermediary to contextualise?

Liability frameworks for AI-generated genetic counselling are entirely undeveloped, which could be a significant adoption barrier even where the technology performs well.

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate (prospective validation is promising; scope and generalisability need independent confirmation)
• Translation Speed: 2–5 years for regulated clinical deployment in high-income settings; 5–10 years for low-resource settings
• Barrier Analysis:
  • Regulatory: AI diagnostic tools require regulatory clearance as Software as a Medical Device (SaMD); genetic counselling AI is in uncharted regulatory territory
  • Reimbursement: AI-assisted rare disease diagnosis reimbursement pathways do not yet exist in most health systems
  • Cost: Cloud-based deployment could make this low-cost per query; initial development and validation costs are substantial
  • Infrastructure: Requires EHR integration and clinical phenotyping data structures; interoperability is a real challenge
  • Awareness: Open-access publication in NPJ Digital Medicine maximises reach; paediatric genetics societies need to evaluate and endorse
  • Equity: The technology's greatest potential is in underserved settings, but deployment barriers (internet connectivity, EHR interoperability, language localisation) are highest in exactly those settings — a classic equity paradox that requires deliberate policy attention

---

[CALL TO ACTION / CLOSING]

For the millions of children worldwide whose diagnosis is delayed for years because the right specialist isn't available, KGRD represents a genuinely hopeful signal — not a solution yet, but proof that AI can reason through rare disease complexity in clinically meaningful ways. The next step is independent multicentre validation across diverse genetic disease populations, and the field should move quickly to provide it.